An autopsy study of brains of non-dementia subjects with reported depression during their lifetime suggests that there are discrete neuropathological correlates of late-life depression (Tsopelas et al. Br J Psychiatry 2011; 198: 109-114).
Neurology
B cell drug set to enter phase III testing
March 30, 2011Ocrelizumab, a novel anti-CD20 monoclonal antibody, is set to enter phase III testing in MS, according to industry newsletter FierceBiotech (www.fiercebiotech.com). The announcement was made at an investor event hosted by Roche. The drug was developed by Genentech, a subsidiary of Roche, and Biogen Idec.
Dalfampridine may improve walking ability: phase III results
March 9, 2011A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502).
Deep brain stimulation: consensus recommendations
March 9, 2011An international consortium has published its recommendations on issues relating to deep brain stimulation (DBS) in patients with Parkinson’s disease (Bronstein et al. Arch Neurol 2010; epublished October 11, 2010).
White matter hyperintensities predict cognitive decline
February 23, 2011White matter hyperintensities are a predictor of cognitive decline in relatively healthy older subjects, according to data from the Alzheimer Disease Neuroimaging Initiative (Carmichael et al. Arch Neurol 2010; 67: 1370-1378).